Evaluation of SEPP1 and Selenoprotein S Gene Polymorphisms (rs7579 and rs34713741) in Relation to Colorectal Cancer Susceptibility in Subset of Iranian Population: A Case–control Study

Abstract

Background: Colorectal cancer (CRC) is rated as the second cause of cancer death worldwide. Selenium (Se) has antioxidant activity and antitumor effect, especially in colon cancer. This important role occurs through selenoproteins. Low Se intake or low plasma Se and selenoproteins concentrations are associated with higher risk of CRC. rs7579 polymorphism in 3’ untranslated region of the SEPP1 gene can effect on selenocysteine incorporation during protein synthesis and also effect on microRNA –messengerRNA interaction and sequentially change in SEPP1 expression. rs34713741 polymorphism as a promoter variant in selenoprotein S ( SELS ) gene can effect on SElS expression and finally lead to increased CRC risk. Methods: A case–control study using 60 CRC patients and 74 noncancerous counterparts were undertaken in order to determine rs7579 and rs34713741 genotypes using real-time polymerase chain reaction high-resolution melting method. Results: We found an association of borderline statistical significance between allele A for rs7579 in SEPP 1 and CRC risk (adjusted odds ratio = 1.63; confidential interval = 0.99–2.07; P = 0.05). The frequency of genotypes rs34713741 of the mentioned polymorphisms was not significantly different between case and control groups ( P = 0.23 and P = 0.93, respectively). Conclusions: The results suggest that these polymorphisms probably has not a substantial role in Iranian CRC risk and is not a serious potential factor in risk assessment of mentioned disease among Iranians.

Genetic Determinants of Selenium Availability, Selenium-Response, and Risk of Polycystic Ovary Syndrome

“…Identi cation of signi cant gene variants associated with Se metabolism A total of ten eligible studies ( fteen SNPs) [29][30][31][32][33][34][35][36][37][38] associating different selenoprotein polymorphisms among various disorders were included after following inclusion and exclusion criteria. The characteristics of these studies comprising gene and its polymorphism, ethnicity, study type, sample size and disorder or conditions were represented in supplementary table 1.…”

Lack of Association between Common Polymorphisms in Selenoprotein P Gene and Susceptibility to Colorectal Cancer, Breast Cancer, and Prostate Cancer: A Meta-Analysis

“…Overall, 10 publications with 14 independent studies on SEPP1 polymorphisms (rs3877899 and rs7579) and cancer susceptibility were available for our meta-analysis [ 10 , 11 , 16 – 23 ], and the publication selection process is displayed in Figure 1 . For rs3877899 polymorphism, nine case-control studies with 7,157 cases and 6,440 controls met the inclusion criteria, including three BC, two CRC, and four PCa studies.…”

“…We think the earlier sentence was correct regarding the genotyping methods used in the included studies. Except for these studies [ 10 , 11 , 20 , 23 ], the genotype distribution in control groups of the enrolled studies was in line with HWE. The selected study characteristics are enumerated in Table 2 .…”

“…Nowadays, more and more studies have demonstrated that several polymorphisms of the selenoprotein P gene ( SEPP1 ) were associated with susceptibility of tumors, including breast cancer (BC) [ 10 ], colorectal cancer (CRC) [ 11 ], and PCa [ 12 ]. However, results from these studies remain inconclusive.…”

Peculiarities of treatment of patients with comorbid pathology: chronic pancreatitis and hypothyroidism, taking into account SEPP1 gene polymorphism (RS7579)

“…Diagnosis and treatment of CP was carried out according to the national Unified Clinical Protocol of Primary and Specialized Medical Care "Chronic Pancreatitis" (2023) [13], the National Clinical Guidelines "Chronic Pancreatitis" (2023) [14]. Treatment of hypothyroidism in patients with CP was carried out according to the clinical practice recommendations of the European Thyroid Association for the treatment of thyroid diseases in 2023 and a number of international organizations [15,16].…”